We are analyzing https://link.springer.com/article/10.1007/bf02988444.

Title:
PET studies in dementia | Annals of Nuclear Medicine
Description:
Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission tomography (PET) and18F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard technique during the past 20 years and is now available at many university hospitals in all highly developed countries. Many studies have documented a close relation between lCMRGlc and localized cognitive functions, such as language and visuoconstructive abilities. Alzheimer’s disease (AD) is characterized by regional impairment of cerebral glucose metabolism in neocortical association areas (posterior cingulate, temporoparietal and frontal multimodal association cortex), whereas primary visual and sensorimotor cortex, basal ganglia, and cerebellum are relatively well preserved. In a multicenter study comprising 10 PET centers (Network for Efficiency and Standardisation of Dementia Diagnosis, NEST-DD) that employed an automated voxel-based analysis of FDG PET images, the distinction between controls and AD patients was 93% sensitive and 93% specific, and even in very mild dementia (at MMSE 24 or higher) sensitivity was still 84% at 93% specificity. Significantly abnormal metabolism in mild cognitive deficit (MCI), indicates a high risk to develop dementia within the next two years. Reduced neocortical glucose metabolism can probably be detected with FDG PET in AD on average one year before onset of subjective cognitive, impairment. In addition to glucose metabolism, specific tracers for dopamine synthesis (18F-F-DOPA), and for (11C-MP4A) are of interest for differentiation among dementia subtypes. Cortical acetylcholine esterase activity (AChE) activity is significantly lower in patients with AD or with dementia with Lewy bodies (DLB) than in age-matched normal controls. In LBD there is also impairment of dopamine synthesis, similar to Parkinson disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, pubmed, cas, article, neurol, disease, dementia, alzheimers, pet, emission, positron, glucose, metabolism, cerebral, herholz, tomography, brain, metabolic, cognitive, imaging, clinical, parkinsons, lewy, med, sci, regional, activity, psychiatry, impairment, study, diagnosis, patients, functional, nucl, mild, alzheimer, analysis, fdg, blood, minoshima, vascular, cortex, cortical, acetylcholine, access, early, system, perani, kuhl,

Topics {✒️}

2-f-18-fluoro-2-deoxy-d-glucose positron-emission tomography incorporating 2-deoxy-2-[18f]fluoro-d-glucose high-resolution technetium-99m-hmpao spect and18f-2-fluoro-2-deoxy-d-glucose magnetic resonance imaging ]fluolo-l-dopa pet study month download article/chapter automated voxel-based analysis long-term outcome resting-state glucose metabolism community-based epidemiological study 18f-fluorodopa pet study activity-dependent energy metabolism geriatric memory dysfunction 1-[11c]methylpiperidin-4-yl propionate nonquantitative [18f]fdg pet multi-tracer pet imaging 18f-f-dopa reciprocal limbic-cortical function brain 18fdg-pet pattern automated analysis multicenter fdg pet acetylcholine esterase activity positron emission tomography full article pdf statistical parametric mapping voxel-based analysis cerebral glucose metabolism van gorp wg brain glucose metabolism occipital glucose metabolism posterior cingulate cortex radioactive acetylcholine analog privacy choices/manage cookies functional brain imaging age-matched normal controls f-18 fdg pet nuclear medicine aims cerebral glucose hypermetabolism regional brain metabolism brain energy metabolism occipital glucose hypometabolism neocortical association areas resting human brain striatal dopamine uptake mohs rc beta-amyloid plaques asymmetrical glucose consumption multicenter study progressive supranuclear palsy

Questions {❓}

Can PET data differentiate Alzheimer’s disease from vascular dementia?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:PET studies in dementia
         description:Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission tomography (PET) and18F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard technique during the past 20 years and is now available at many university hospitals in all highly developed countries. Many studies have documented a close relation between lCMRGlc and localized cognitive functions, such as language and visuoconstructive abilities. Alzheimer’s disease (AD) is characterized by regional impairment of cerebral glucose metabolism in neocortical association areas (posterior cingulate, temporoparietal and frontal multimodal association cortex), whereas primary visual and sensorimotor cortex, basal ganglia, and cerebellum are relatively well preserved. In a multicenter study comprising 10 PET centers (Network for Efficiency and Standardisation of Dementia Diagnosis, NEST-DD) that employed an automated voxel-based analysis of FDG PET images, the distinction between controls and AD patients was 93% sensitive and 93% specific, and even in very mild dementia (at MMSE 24 or higher) sensitivity was still 84% at 93% specificity. Significantly abnormal metabolism in mild cognitive deficit (MCI), indicates a high risk to develop dementia within the next two years. Reduced neocortical glucose metabolism can probably be detected with FDG PET in AD on average one year before onset of subjective cognitive, impairment. In addition to glucose metabolism, specific tracers for dopamine synthesis (18F-F-DOPA), and for (11C-MP4A) are of interest for differentiation among dementia subtypes. Cortical acetylcholine esterase activity (AChE) activity is significantly lower in patients with AD or with dementia with Lewy bodies (DLB) than in age-matched normal controls. In LBD there is also impairment of dopamine synthesis, similar to Parkinson disease.
         datePublished:
         dateModified:
         pageStart:79
         pageEnd:89
         sameAs:https://doi.org/10.1007/BF02988444
         keywords:
            PET
            dementia
            multicenter study
            automated image analysis
            Alzheimer disease
            glucose metabolism
            acetylcholine
            dopamine
            Nuclear Medicine
            Imaging / Radiology
         image:
         isPartOf:
            name:Annals of Nuclear Medicine
            issn:
               1864-6433
               0914-7187
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Karl Herholz
               affiliation:
                     name:Max-Planck-Institut für neurologische Forschung
                     address:
                        name:Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Köln, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:PET studies in dementia
      description:Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission tomography (PET) and18F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard technique during the past 20 years and is now available at many university hospitals in all highly developed countries. Many studies have documented a close relation between lCMRGlc and localized cognitive functions, such as language and visuoconstructive abilities. Alzheimer’s disease (AD) is characterized by regional impairment of cerebral glucose metabolism in neocortical association areas (posterior cingulate, temporoparietal and frontal multimodal association cortex), whereas primary visual and sensorimotor cortex, basal ganglia, and cerebellum are relatively well preserved. In a multicenter study comprising 10 PET centers (Network for Efficiency and Standardisation of Dementia Diagnosis, NEST-DD) that employed an automated voxel-based analysis of FDG PET images, the distinction between controls and AD patients was 93% sensitive and 93% specific, and even in very mild dementia (at MMSE 24 or higher) sensitivity was still 84% at 93% specificity. Significantly abnormal metabolism in mild cognitive deficit (MCI), indicates a high risk to develop dementia within the next two years. Reduced neocortical glucose metabolism can probably be detected with FDG PET in AD on average one year before onset of subjective cognitive, impairment. In addition to glucose metabolism, specific tracers for dopamine synthesis (18F-F-DOPA), and for (11C-MP4A) are of interest for differentiation among dementia subtypes. Cortical acetylcholine esterase activity (AChE) activity is significantly lower in patients with AD or with dementia with Lewy bodies (DLB) than in age-matched normal controls. In LBD there is also impairment of dopamine synthesis, similar to Parkinson disease.
      datePublished:
      dateModified:
      pageStart:79
      pageEnd:89
      sameAs:https://doi.org/10.1007/BF02988444
      keywords:
         PET
         dementia
         multicenter study
         automated image analysis
         Alzheimer disease
         glucose metabolism
         acetylcholine
         dopamine
         Nuclear Medicine
         Imaging / Radiology
      image:
      isPartOf:
         name:Annals of Nuclear Medicine
         issn:
            1864-6433
            0914-7187
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Karl Herholz
            affiliation:
                  name:Max-Planck-Institut für neurologische Forschung
                  address:
                     name:Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Köln, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Nuclear Medicine
      issn:
         1864-6433
         0914-7187
      volumeNumber:17
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Max-Planck-Institut für neurologische Forschung
      address:
         name:Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Köln, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Karl Herholz
      affiliation:
            name:Max-Planck-Institut für neurologische Forschung
            address:
               name:Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Köln, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Köln, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(308)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.75s.

LINK . SPRINGER . COM {}